Evolved By Nature is a technology company.
Evolved By Nature has raised $190.0M across 2 funding rounds.
Evolved By Nature has raised $190.0M in total across 2 funding rounds.
Evolved by Nature is a biotechnology company that develops sustainable, high-performance ingredients using its proprietary Activated Silk™ technology, derived from natural silk proteins.[1][3][4] The company creates biomolecules and peptides for applications in skincare, beauty, fashion, textiles, leather, personal care, and biomedicine, serving brands and manufacturers seeking to replace petrochemicals with bio-based alternatives that enhance product performance, skin health, and environmental sustainability.[2][3][5] It addresses the problem of harmful synthetic chemicals by offering natural, upcycled ingredients that support skin barrier function, reduce water loss, and promote regeneration, with proven clinical results outperforming ceramides in low-viscosity formulas.[1][4] Growth momentum includes recent launches of biotech beauty peptides like Activated Silk™ 33B, partnerships with major skincare and leather brands (e.g., Ogee), 41 patents in synthetic fibers and silk polymers, and expansion into therapeutics and supply chains.[1][3][4]
Founded in 2013 in Boston, Massachusetts (originally as Silk Therapeutics, Inc., later rebranded to Evolved by Nature), the company emerged from founders Randi Altman and Matt Lacouture's vision to leverage silk cocoons for innovative biotech applications.[1][4][5] Altman and Lacouture initially targeted petrochemical-free skincare due to silk peptides' biocompatibility with human skin, but discovered broader potential in barrier protection for textiles, leather, medicine, and more.[5] Early traction built on biotechnology and chemical engineering to produce pure silk peptide concentrates, leading to products like gel hand sanitizers and soaps during COVID-19, and pivotal expansions into high-performance molecules for global brands.[1][5][7] Based in Medford/Boston, the company sources from responsible sericulture farms in Japan, emphasizing pesticide-free mulberry and ethical silkworm practices.[6]
Evolved by Nature rides the wave of sustainable biotech and green chemistry, capitalizing on rising demand for bio-based alternatives amid regulatory pressures on petrochemicals, PFAS bans, and consumer shifts toward eco-friendly, high-performance products in beauty, fashion, and healthcare.[1][3][6] Timing aligns with biotech advancements in peptide discovery and circular economy trends, enabling replacement of legacy chemicals in trillion-dollar industries like skincare (projected growth via natural ingredients) and textiles.[2][5] Market forces favoring it include supply chain sustainability mandates, UN SDG alignment, and partnerships with family sericulture farms for ethical sourcing, positioning it ahead of competitors like AGAE Technologies (biosurfactants) and Elevance (renewable chemicals).[1][6] It influences the ecosystem by pioneering "better-natured" molecules that expand biomedicine boundaries, boost product performance, and scale via investors like Ontario Teachers' Pension Plan, fostering industry-wide adoption of silk biotech.[5]
Evolved by Nature is poised to scale its Activated Silk™ platform into aesthetic medicine, therapeutics, and global supply chains, with upcoming peptide launches and applications unlocking "infinite uses" for one protein.[3][5] Trends like regenerative skincare, PFAS-free materials, and bio-innovation hubs (e.g., Boston) will propel growth, potentially disrupting petrochemistry dominance through clinical validations and brand integrations.[4][6] Its influence may evolve from niche innovator to ecosystem leader, as sustainable molecules become standard—proving that advancing planetary health directly elevates product performance, much like its silk origins transformed cocoons into high-impact biotech.[1][3]
Evolved By Nature has raised $190.0M in total across 2 funding rounds.
Evolved By Nature's investors include Stadia Ventures.
Evolved By Nature has raised $190.0M across 2 funding rounds. Most recently, it raised $120.0M Series C in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $120.0M Series C | Stadia Ventures | |
| Dec 1, 2021 | $70.0M Series B | Stadia Ventures |